Remission in early rheumatoid arthritis -- a comparison of new ACR/EULAR remission criteria to established criteria.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 22505708.
- Also identified by DOI 10.3899/jrheum.111341.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To describe the frequency of remission in an early rheumatoid arthritis (ERA) cohort. The frequency of remission was evaluated, based on 8 definitions including the Boolean-based American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria. Of 369 patients, remission at 12 months ranged from 18% according to the ACR/EULAR clinical trial criteria to 40% according to the 28-joint Disease Activity Score (DAS28) < 2.6. Higher tender joint count, swollen joint count, and physician global scores were seen for DAS28-based definitions, and patient global assessment (PtGA) scores were almost 5-fold higher for DAS28 remission. Remission is achievable in ERA but its frequency differs according to the remission definition applied. Adoption of the new ACR/EULAR definition will limit the number classified as in remission, especially if the PtGA criteria are rated high for reasons other than inflammatory arthritis.
Medical subject headings
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Outcome Assessment, Health Care